Unusual Options Activity Insight: Biogen
Biogen (NASDAQ:BIIB) shares experienced unusual options activity on Tuesday. The stock price moved down to $343.7 following the option alert.
Lundbeck Out Licenses Flopped Alzheimer’s Drug In Wake Of Biogen’s Controversial Success With Aducanumab
Privately-held Denovo Biopharma LLC has in-licensed global rights for idalopirdine from H. Lundbeck A/S (OTC:HLUYY) for all indications. The deal gives Lundbeck the option…
Biogen Publishes Trial Titled ‘Exploring Diroximel Fumarate Real-world Experience in Canada and Israel’ To ClinicalTrials.Gov Site
https://clinicaltrials.gov/ct2/show/NCT04948606
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.
Biogen’s Costly Alzheimer’s Treatment May Face Restricted Medicare Access: WSJ
The recent approval of Biogen Inc’s (NASDAQ:BIIB) high-price Alzheimer’s drug is raising questions about who will have access to the $56,000/year treatment…
Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease, Presenting at AAIC & Headed to Phase 2 Trials
Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company’s corporate outlook, Green participated in a panel entitled “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan.”
10 Biggest Price Target Changes For Monday
Barclays raised the price target for Accenture plc (NYSE: ACN) from $310 to $335. Accenture shares rose 1.1% to close at $294.66 on Friday.
RBC Capital Maintains Sector Perform on Biogen, Lowers Price Target to $354
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Sector Perform and lowers the price target from $400 to $354.
Alzheimer’s Biotech Acumen Pharmaceuticals Prices $125M IPO Soon After Biogen’s Aduhelm Approval
Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in Alzheimer’s disease.